• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Coulter posts losses in fiscal 1999

Article

Radiopharmaceutical firm Coulter Pharmaceuticals reported losses for both the fourth quarter and fiscal year 1999 (end-December). The company posted quarter losses of $14.5 million, compared to net income of $25.5 million in 1998, and dramatic year-end

Radiopharmaceutical firm Coulter Pharmaceuticals reported losses for both the fourth quarter and fiscal year 1999 (end-December). The company posted quarter losses of $14.5 million, compared to net income of $25.5 million in 1998, and dramatic year-end losses of $50.6 million, compared to $2 million the year before. The South San Francisco, CA, company attributed these results to increased operating expenses to support its R&D and commercialization activities for Bexxar, the cancer therapy product Coulter is developing with SmithKline Beecham for the treatment of non-Hodgkin’s lymphoma. Coulter ended the year with cash assets of $82 million.

In other Coulter news, the firm has received a composition patent from the U.S. Patent and Trademark Office. Arising from Coulter’s work on Bexxar, the patent covers radiolabeled monoclonal antibodies for the treatment of B-cell lymphomas, and strengthens Coulter’s position in the field of radioimmunotherapy, according to president and CEO Michael Bigham.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.